


Apremilast Most Helpful for Mild to Moderate Psoriatic Arthritis

FDA Update: New Drug Approvals, New & Expanded Indications, & More

Risankizumab & Apremilast Come to Market in Canada

Case Report: A Patient on Apremilast Develops Streptococcus Salivarius

Rheumatology Drugs at a Glance, Part 2: Psoriasis

Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

Long-Term Apremilast Promising for Psoriatic Arthritis

Study Results for 9 New Psoriatic Arthritis Drugs
